VRK1 promotes DNA-induced type I interferon production

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Type I interferons (IFNs) are critical cytokines with antitumor, antiviral, and immunoregulatory functions.
• Dysregulated type I IFN production is implicated in autoimmune disorders, necessitating precise control of their signaling pathways.
• Identifying novel regulators of type I IFN signaling is essential for maintaining immune homeostasis.

Purpose of the Study:

• To identify a novel regulator of type I interferon signaling.
• To investigate the role of Vaccinia-related kinase 1 (VRK1) in the induction of type I IFNs.

Main Methods:

• In vitro models using primary mouse bone marrow-derived macrophages (BMDMs) and human/murine cell lines (HEK293, Hela, MEF).
• VRK1 knockdown using RNA interference.
• Real-time PCR and dual-luciferase reporter assays to measure type I IFN and IFN-stimulated gene (ISG) expression.
• Treatment with VRK1 inhibitor (VRK-IN-1) to assess its impact on type I IFN induction.
• Analysis of the cGAS-STING-IFN-I axis.

Main Results:

• Knockdown of VRK1 significantly attenuated the induction of type I IFNs and ISGs upon stimulation with HTDNA and Poly (dA:dT).
• The VRK1 inhibitor VRK-IN-1 suppressed type I IFN and ISG induction in both human and murine cell lines, as well as in primary mouse BMDMs.
• VRK1 was found to potentiate the cGAS-STING-IFN-I axis response at the STING level.

Conclusions:

• Vaccinia-related kinase 1 (VRK1) plays a novel role in regulating type I interferon production.
• VRK-IN-1, a selective VRK1 inhibitor, demonstrates potential as a therapeutic lead compound for suppressing aberrant type I IFN activity in autoimmune diseases.